STOCK TITAN

Moleculin completes Part A; trial data expected Q1 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) reported third-quarter financial results and said treatment of all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial is complete. Comprehensive Part A data are expected in the first quarter of 2027 and are expected to support selection of an Annamycin dose for Part B, currently planned to begin in the first half of 2027.

For the quarter ended September 30, 2026, research and development expense was $4.488 million, compared with $3.738 million a year earlier; general and administrative expense was $2.114 million, compared with $2.147 million. Net loss was $6.493 million, compared with $25.399 million, primarily reflecting the absence of the prior-year $20.609 million non-cash loss on issuance of warrant liabilities. Cash and cash equivalents were $7.287 million as of September 30, 2026, versus $8.878 million as of December 31, 2025. Moleculin said its clinical trials require significant additional financing, for which it has no commitments.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointMIRACLE completed treatment for all 90 Part A patients.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash was $7.287 million; clinical trials require significant financing, with no commitments.

Filing Explained

At September 30, 2026, Moleculin reported $7.287 million in cash, equivalent to 74.7 days of third-quarter operating cash use at the reported rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $7,287,000 / ($8,970,000 / 92) = 74.7 days
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Research and development expense $4.488 million Three months ended September 30, 2026; $3.738 million in the same period of 2025
General and administrative expense $2.114 million Three months ended September 30, 2026; $2.147 million in the same period of 2025
Net loss $6.493 million Three months ended September 30, 2026; $25.399 million in the same period of 2025
Cash and cash equivalents $7.287 million As of September 30, 2026; $8.878 million as of December 31, 2025
Net cash used in operating activities $21.7 million Nine months ended September 30, 2026
Prior-year non-cash loss on issuance of warrant liabilities $20.609 million Three months ended September 30, 2025
Patients completing Part A treatment 90 patients MIRACLE trial Part A
Expected Part A data readout First quarter of 2027 Comprehensive data from the MIRACLE trial's Part A
pivotal medical
"pivotal Phase 2/3 MIRACLE trial"
Pivotal describes a test, event, or decision that is decisive for whether a product, idea, or plan moves forward—most often used for a late-stage clinical trial or a regulatory review whose result determines approval or rejection. Investors care because a positive outcome typically unlocks major value (like market access or sales), while a negative one can sharply reduce expected future revenue; think of it as the final exam that decides whether a project passes or fails.
adaptive design medical
"pivotal, adaptive design, multi-center, randomized"
Adaptive design is a way to run clinical trials that lets researchers change aspects of the study—such as dose, sample size, or which patient groups are studied—based on data gathered while the trial is ongoing, without starting over. For investors, it matters because this flexibility can shorten development time, reduce costs, and increase the chance of finding a successful outcome, similar to steering a ship toward calmer waters as conditions change.
relapsed or refractory acute myeloid leukemia medical
"treatment of relapsed or refractory acute myeloid leukemia"
A form of acute myeloid leukemia (AML) that either returns after an initial period of remission (relapsed) or fails to respond to standard treatments (refractory). It matters to investors because these cases represent a clear unmet medical need and drive demand for new drugs, clinical trials, and regulatory attention—similar to crops that either regrow after being cleared or resist the usual weed control, prompting investment in better solutions.
AnnAraC medical
"together referred to as AnnAraC"
warrant liability financial
"Gain from change in fair value of warrant liability"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
cardiotoxicity medical
"lack the cardiotoxicity common with currently prescribed anthracyclines"
Cardiotoxicity is damage to the heart caused by a drug, chemical or medical treatment that can weaken heart function, disrupt heartbeat or cause inflammation. It matters to investors because evidence of cardiotoxicity can halt or delay product approvals, trigger costly additional testing, recalls or legal risk, and reduce future revenue potential—similar to how rust in an engine can undermine a machine’s reliability and resale value.
Research and development expense, third quarter $4.488 million Compared with $3.738 million in the third quarter of 2025
General and administrative expense, third quarter $2.114 million Compared with $2.147 million in the third quarter of 2025
Net loss, third quarter $6.493 million Compared with $25.399 million in the third quarter of 2025
Cash and cash equivalents $7.287 million Compared with $8.878 million as of December 31, 2025
Net cash used in operating activities, nine months $21.7 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was MBRX's third-quarter 2026 net loss?

Moleculin reported a $6.493 million net loss for the quarter ended September 30, 2026, compared with $25.399 million a year earlier. The decrease primarily reflected the absence of the prior-year $20.609 million non-cash loss on issuance of warrant liabilities.

When does MBRX expect data from the MIRACLE trial's Part A?

Moleculin expects comprehensive Part A data in the first quarter of 2027. The data are expected to support selection of an Annamycin dose for Part B, which is currently planned to begin in the first half of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001659617 0001659617 2026-11-16 2026-11-16
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 16, 2026
 
mbrx20261114_8kimg001.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation
or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
1 / 2

 
Item 2.02
Results of Operations and Financial Condition.
 
On November 16, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026, and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)     Exhibits.
 
Exhibit
No.
Description
 
 
99.1
Press Release dated November 16, 2026
 
 
104
Cover page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC.
   
   
 
Date:  November 16, 2026
   
 
By:  /s/ Jonathan P. Foster 
 
Jonathan P. Foster
 
Chief Financial Officer
 
 
2 / 2
 

Exhibit 99.1

 logo.jpg

Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout

 

 

-

Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)

 

 

-

Comprehensive Part A data readout remains on track for the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B

 

 

-

Annamycin's differentiated cardiac safety profile further supported by peer-reviewed analysis of 90 patients across five clinical trials, with no evidence of clinical or subclinical cardiotoxicity at first interim analysis

 

 

-

New preclinical findings suggest Annamycin may help turn immunologically “cold” pancreatic tumors “hot,” supporting potential combination treatment approaches

 

HOUSTON, November 16, 2026 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), reported on Friday the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).

 

Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.

 

"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin's clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin "

 

 

 

"What gives us confidence as we approach this readout is the totality of evidence generated to date," continued Mr. Klemp. "We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones."

 

Recent Highlights

 

 

●

Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. The full Part A dataset is expected to inform optimal dose selection for the planned initiation of Part B.

 

●

Published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma. The analysis, independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.

 

●

Presented new preclinical data at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer indicating that Annamycin's antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity. These findings suggest Annamycin may help expose immunologically “cold” tumors to immune attack, potentially supporting combination treatment approaches.

 

●

Announced acceptance of data from the MIRACLE trial for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. The presentation will highlight interim results from the pivotal Phase 2/3 trial in patients with relapsed or refractory AML.

 

Expected Milestones for the Annamycin Development Program

 

 

●

Q1 2027: MIRACLE – Comprehensive Part A data readout following completion of treatment for all 90 patients

 

●

1H 2027: MIRACLE – Planned initiation of Part B following optimal dose selection

 

●

1H 2027: Planned initiation of physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer

 

●

1H 2028: Planned initiation of third-line relapsed/refractory AML subject trial

 

●

1H 2028: Planned initiation of pediatric AML clinical study

 

●

2H 2028: Complete recruitment of Part B

 

●

2H 2028: Primary efficacy data for MIRACLE 2nd line subjects

 

●

2028-2029: Begin a rolling submission of a New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE

 

 

 

Additional Pipeline Programs

 

Moleculin continues to support development activities for its WP1066 program through investigator-sponsored research, including a physician-sponsored Phase 1B/2 clinical trial evaluating WP1066 in combination with radiation for the treatment of glioblastoma. These programs complement Moleculin's primary focus on advancing Annamycin.

 

Third Quarter 2026 Financial Results

 

Research and development expenses were approximately $4.5 million for the three months ended September 30, 2026, compared to approximately $3.7 million for the same period in 2025. The increase was primarily attributable to activities related to the MIRACLE clinical trial.

 

General and administrative expenses were approximately $2.1 million for the three months ended September 30, 2026, compared to approximately $2.1 million for the same period in 2025.

Net loss for the third quarter of 2026 was approximately $6.5 million, compared to approximately $25.4 million for the same period in 2025. The decrease in net loss was primarily attributable to the absence of the approximately $20.6 million non-cash loss on the issuance of warrant liabilities recorded in the prior-year period.

 

For the nine months ended September 30, 2026, research and development expenses were approximately $15.3 million, compared to approximately $10.8 million for the same period in 2025. The increase was primarily related to the MIRACLE clinical trial, additional nonclinical studies and other research costs. General and administrative expenses were approximately $6.7 million for the nine months ended September 30, 2026, compared to approximately $6.7 million for the same period in 2025.

 

As of September 30, 2026, Moleculin had cash and cash equivalents of approximately $7.3 million, compared to approximately $8.9 million as of December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $21.7 million.

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

 

 

 

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

 

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

 

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

 

Forward-Looking Statements

 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation: the potential efficacy and safety of Annamycin; the potential for Annamycin to be used in combination with immune checkpoint inhibitors or in indications other than AML; the timing and results of the comprehensive Part A data readout of the MB-108 trial; the planned initiation of Part B of the MIRACLE trial in the first half of 2027 and the expected timeline for completing Part B recruitment; the potential for the MB-108 trial to support a New Drug Application submission, including the anticipated rolling NDA submission during 2028-2029; the planned initiation of a third-line relapsed/refractory AML clinical study and a pediatric AML clinical study, each anticipated in the first half of 2028; the Company’s plans to sponsor an investigator-initiated clinical trial of Annamycin in pancreatic cancer; and the Company’s ability to secure additional financing to conduct its clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the completion of the clinical trials described in this press release assumes the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

Investor Contact:
JTC Team, LLC

Jenene Thomas

(908) 824-0775

MBRX@jtcir.com

 

 

 

Moleculin Biotech, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in thousands)

 

September 30, 2026

   

December 31, 2025

 

Current assets:

               

Cash and cash equivalents

  $ 7,287     $ 8,878  

Prepaid expenses and other current assets

    1,124       808  

Total current assets

    8,411       9,686  

Intangible assets

    11,148       11,148  

Other non-current assets

    900       900  

Operating lease right-of-use asset

    223       314  

Furniture and equipment, net

    54       78  

Total assets

  $ 20,736     $ 22,126  
                 

Current liabilities:

               

Accounts payable and other current liabilities

  $ 6,135     $ 6,854  

Total current liabilities

    6,135       6,854  

Operating lease liability - long-term, net of current portion

    107       222  

Warrant liability - long term

    5       44  

Total liabilities

    6,247       7,120  

Total stockholders' equity

    14,489       15,006  

Total liabilities and stockholders' equity

  $ 20,736     $ 22,126  

 

 

 

 

Unaudited Condensed Consolidated Statements of Operations

   

Three Months Ended

September 30,

   

Nine Months Ended September 30,

 

(in thousands, except share and per share amounts)

 

2026

   

2025

   

2026

   

2025

 

Revenues

  $ -     $ -     $ -     $ -  

Operating expenses:

                               

Research and development

    4,488       3,738       15,317       10,774  

General and administrative

    2,114       2,147       6,705       6,715  

Depreciation and amortization

    8       21       24       81  

Total operating expenses

    6,610       5,906       22,046       17,570  

Loss from operations

    (6,610 )     (5,906 )     (22,046 )     (17,570 )

Other income (loss):

                               

Gain from change in fair value of warrant liability

    35       1,591       10,798       1,031  

Transaction costs allocated to equity and liability warrant issuances

    (12 )     (530 )     (707 )     (1,737 )

Loss on issuance of warrant liabilities

    -       (20,609 )     (15,158 )     (30,962 )

Other income, net

    36       16       125       30  

Interest income, net

    58       39       15       96  

Net loss

  $ (6,493 )   $ (25,399 )   $ (26,973 )   $ (49,112 )

Warrant deemed dividends

    (773 )     -       (2,867 )     -  

Net loss available to common stockholders

  $ (7,266 )   $ (25,399 )   $ (29,840 )   $ (49,112 )

Net loss per common share - basic and diluted

  $ (9.59 )   $ (340.43 )   $ (71.38 )   $ (1,179.03 )

Weighted average common shares outstanding - basic and diluted

    757,858       74,609       418,060       41,655  

 

 

Filing Exhibits & Attachments

5 documents

Keep reading